Page URL:

'Genetically-guided' supplements company settles after Federal Trade Commission lawsuit

20 January 2014
Appeared in BioNews 738

A biotechnology company that produces genetically customised nutritional supplements has settled charges of deceptive advertising with the US Federal Trade Commission (FTC) over claims that its products could treat a number of ailments and diseases.

GeneLink Biosciences, and its former subsidiary, Foru International, marketed skincare serums and nutritional supplements, each costing over US $100 a month. Based on DNA obtained from a cheek swab, the products were designed to be 'customised' to each customer's genetic make up.

However, the companies were charged with deceptive advertising after the FTC alleged that they had violated US federal law by making 'false or unsupported health claims about their genetically customized products'.

In its complaint, the FTC outlined how company-approved marketing stated that the skincare products were scientifically proven and that their nutritional supplements could compensate for a person's genetic 'disadvantages'. The companies also claimed through testimonials that the nutritional products could treat conditions such as diabetes, heart disease and insomnia, explained the FTC.

In accordance with the settlement made, the companies will no longer be able to state that their products can help with medical conditions without conducting at least two properly controlled and reviewed trials. In addition, both GeneLink and Foru International will be audited every two years for the next twenty years to ensure that they're compliant with the settlement.

Jessica Rich, the director of the FTC's Bureau of Consumer Protection, said in the statement: 'This case is about the consequences of making false claims. It doesn't matter whether the claims deal with the benefits of direct-to-consumer genetic testing or the privacy of personal information. It's against the law to deceive people about your product and to make promises you don't keep'.

The Federal Trade Commission also brought charges of failing to secure customer information properly, including genetic data, bank account information and social security numbers, claiming that up to 30,000 customers could have been affected.

Companies Pitching Genetically Customized Nutritional Supplements Will Drop Misleading Disease Claims
Federal Trade Commission (press release) |  7 January 2014
GeneLink Settles
The Scientist |  14 January 2014
Personal genetics firm GeneLink hit with an FTC lawsuit for false advertising
The Verge |  11 January 2014
25 November 2019 - by Dr Katie Howe 
A health watchdog group have petitioned US regulators to take action against the manufacturers of 39 dietary supplements that claim to aid fertility...
16 November 2015 - by Lone Hørlyck 
The US Food and Drug Administration has sent warning letters to three gene-testing companies over the marketing and selling of what it claims are direct-to-consumer gene testing products without its approval...
9 December 2013 - by Ruth Saunders 
Genetic testing company 23andMe, which last week suspended the sale of its health-related genetic tests, is now facing a class action lawsuit in California over its marketing claims....
2 December 2013 - by Ruth Saunders 
The US Food and Drug Administration has ordered 23andMe to 'immediately discontinue' its Personal Genome Service after failing to undergo proper agency approval for its marketing claims...
11 March 2013 - by Cristy Gelling 
In the decade since the human genome was first sequenced, the cost of reading a human genome has dropped from around US $100,000,000 to around US $6,000. In the past year the target has shifted from the '$1000 genome' to the '$0 genome'...
21 August 2006 - by Dr Kathy L Hudson 
While some have warned of the emergence of 'genetic exceptionalism' - the fear that genetic medicine will be treated differently than, and regulated separately from, conventional medicine - the sad reality is that genetics has been ignored by US health oversight agencies such as the Centers for Medicare and Medicaid Services (CMS...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.